Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses

Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis

(2022) Rainer Höhl et al.   MYCOSES

Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation

(2022) Lisa Kriegl et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole for COVID-19-Associated Invasive Mold Infections

(2022) Nadir Ullah et al.   Journal of Fungi

Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study

(2021) Tobias Lahmer et al.   PLoS One

Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole

(2021) Malene Risum et al.   Antibiotics-Basel

Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011–2019)

(2021) Michael A. Pfaller et al.   JOURNAL OF ANTIBIOTICS

Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review

(2021) Elodie Matusik et al.   THERAPEUTIC DRUG MONITORING

Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study

(2021) Jean-Pierre Gangneux et al.   Lancet Respiratory Medicine

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?

(2021) Pier Giorgio Cojutti et al.   Pharmaceutics

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#

(2020) Mohd H. Abdul-Aziz et al.   INTENSIVE CARE MEDICINE

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?

(2020) Quentin Allard et al.   Pharmaceutics

Towards precision medicine: Therapeutic drug monitoring–guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity

(2020) Jaclyn A Cusumano et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

(2020) Michele Bartoletti et al.   CLINICAL INFECTIOUS DISEASES

Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

(2020) Paul E. Verweij et al.   INTENSIVE CARE MEDICINE

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations

(2020) Christoph Zurl et al.   Journal of Fungi

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

(2020) Philipp Koehler et al.   LANCET INFECTIOUS DISEASES

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

(2019) Jesus Ruiz et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy

(2019) E Furfaro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Impact of triazole therapeutic drug monitoring availability and timing

(2019) Erin K. McCreary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Influence of Sustained Low-Efficiency Dialysis (SLED) treatment on Isavuconazole plasma levels in critically ill patients

(2019) Tobias Lahmer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy

(2019) M Biagi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach

(2019) Théo Willeman et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Altered Pharmacokinetics and Dosing of Liposomal Amphotericin B and Isavuconazole during Extracorporeal Membrane Oxygenation

(2019) Yanjun Zhao et al.   PHARMACOTHERAPY

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

(2018) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

(2018) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study

(2018) Alexander F A D Schauwvlieghe et al.   Lancet Respiratory Medicine

Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients

(2018) Xuemei Wu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intensive care medicine research agenda on invasive fungal infection in critically ill patients

(2017) Matteo Bassetti et al.   INTENSIVE CARE MEDICINE

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs

(2017) Jochem B Buil et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

(2016) Vidmantas Petraitis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

(2016) Laura L. Kovanda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

(2016) Amit Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH

(2016) Anne Schmitt-Hoffmann et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Utility of voriconazole therapeutic drug monitoring: a meta-analysis

(2016) Me-Linh Luong et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit

(2016) Yan Wang et al.   PHARMACOTHERAPY

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent

(2015) Marisa H. Miceli et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics

(2013) Hoai-Thu Thai et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective

(2012) P. L. Bonate et al.   AAPS Journal

Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation

(2012) Kiran Shekar et al.   JOURNAL OF CRITICAL CARE

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Therapeutic Drug Monitoring of Voriconazole and Posaconazole

(2011) Trana Hussaini et al.   PHARMACOTHERAPY

Simultaneous Quantification of Voriconazole and Its N-Oxide Metabolite in Human Plasma by an Easy and Rapid Isocratic LC Method with UV Detection

(2008) Céline Eiden et al.   CHROMATOGRAPHIA

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R

(2008) Emmanuelle Comets et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE